XENETIC BIOSCIENCES INC(NASDAQ:XBIO) stock News

XBIO Latest News, Press Relases and Analysis

All

Press Releases

8 hours ago - By: Chartmill - Mentions: SLE NVX VG PTGX ...

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

10 hours ago - By: Chartmill - Mentions: NVX PTGX APM ANVS ...

Which stocks are experiencing notable movement on Friday?

6 hours ago - By: Benzinga - Mentions: MU GLTO

Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges

10 hours ago - By: Benzinga - Mentions: ONMD ANVS PTGX APM ...

12 Health Care Stocks Moving In Friday's Intraday Session

13 hours ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

2 days ago - By: Chartmill - Mentions: PBM HELE AMBO ZCMD ...

Which stocks are moving before the opening bell on Thursday?

2 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

2 months ago - By: Zacks Investment Research - Mentions: CASI

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

2 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

3 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

3 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic

5 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

7 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

7 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

7 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

8 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

a year ago - By: BusinessInsider

XENETIC BIOSCIENCES INC (XBIO) Stock News

XBIO Latest News, Press Relases and Analysis

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

Which stocks are experiencing notable movement on Friday?

Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges

12 Health Care Stocks Moving In Friday's Intraday Session

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Which stocks are moving before the opening bell on Thursday?

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024